Quantitative PCR-Based Method to Assess Cell-Free DNA Quality, Adjust Input Mass, and Improve Next-Generation Sequencing Assay Performance.


Journal

The Journal of molecular diagnostics : JMD
ISSN: 1943-7811
Titre abrégé: J Mol Diagn
Pays: United States
ID NLM: 100893612

Informations de publication

Date de publication:
06 2022
Historique:
received: 30 08 2021
revised: 19 12 2021
accepted: 16 02 2022
pubmed: 2 4 2022
medline: 15 6 2022
entrez: 1 4 2022
Statut: ppublish

Résumé

Cell-free (cf)DNA-based testing has undergone increasingly wide adoption, including assays for the detection of circulating tumor DNA. Due to nucleosome protection, cfDNA has a distinctive fragment size of 160 to 180 bp. However, cfDNA can be contaminated with high molecular weight genomic DNA from blood cells released in plasma during sample collection. Such contamination can lead to decreased sensitivity or inconsistent results in cfDNA next-generation sequencing assays. This article describes a technical advancement in which a quantitative PCR method is used for high molecular weight contamination assessment and input mass adjustment, and has been demonstrated to improve consistency of performance in a circulating tumor DNA next-generation sequencing workflow.

Identifiants

pubmed: 35364322
pii: S1525-1578(22)00074-5
doi: 10.1016/j.jmoldx.2022.02.005
pii:
doi:

Substances chimiques

Cell-Free Nucleic Acids 0
Circulating Tumor DNA 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

566-575

Informations de copyright

Copyright © 2022 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Auteurs

Seng Lor Saelee (SL)

Roche Sequencing Solutions, Inc., Pleasanton, California.

Alexander F Lovejoy (AF)

Roche Sequencing Solutions, Inc., Pleasanton, California.

Bernd Hinzmann (B)

Roche Sequencing Solutions, Inc., Potsdam, Germany.

Katrina Mayol (K)

Roche Sequencing Solutions, Inc., Pleasanton, California.

Samantha Huynh (S)

Roche Sequencing Solutions, Inc., Pleasanton, California.

Amy Harrell (A)

Roche Sequencing Solutions, Inc., Pleasanton, California.

Josh Lefkowitz (J)

Roche Sequencing Solutions, Inc., Pleasanton, California.

Niharika Deodhar (N)

Roche Sequencing Solutions, Inc., Pleasanton, California.

Gladys Garcia-Montoya (G)

Roche Sequencing Solutions, Inc., Pleasanton, California.

Stephanie J Yaung (SJ)

Roche Sequencing Solutions, Inc., Pleasanton, California. Electronic address: stephanie.yaung@roche.com.

Daniel M Klass (DM)

Roche Sequencing Solutions, Inc., Pleasanton, California. Electronic address: dan.klass@roche.com.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH